Treatment with 2-hydroxypropyl-β-cyclodextrin (2HPβCD) increased B-cell lymphoma-2 (BCL-2) expression in a TFEB-dependent manner, inhibiting VSMC apoptosis induced by β-aminopropionitrile and Ang II, thereby mitigating AAA formation and progression [227]. Here, BCL2 is linked to triple-A syndrome.